Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2012

Substantive Development Milestone Payments Eligible To Receive Under Astellas Collaboration Agreement

The remaining $277.0 million in substantive development milestone payments the Company is eligible to receive under the Astellas Collaboration Agreement are as follows:

Milestone Event	4th line prostate  cancer patients(1)			3rd line prostate  cancer patients(2)		2nd line prostate  cancer patients(3)(4)
First acceptance for filing of a marketing application in:
The U.S.			(5)	$	10 million	$	15 million
The first major country in Europe			(5)	$	5 million	$	10 million
Japan	$	5 million		$	5 million	$	10 million
First approval of a marketing application in:
The U.S.			(5)	$	30 million	$	60 million
The first major country in Europe	$	15 million		$	15 million	$	30 million
Japan	$	15 million		$	15 million	$	30 million

(1) Defined as prostate cancer patients who meet each of the following three criteria: (a) prior treatment failure on either (i) one or more luteinizing hormone-releasing hormone, or LHRH, analog drugs or (ii) surgical castration; (b) prior treatment failure on one or more androgen receptor antagonist drugs; and (c) prior treatment failure on chemotherapy.

(2) Defined as prostate cancer patients who meet each of the following three criteria: (a) prior treatment failure on either (i) one or more LHRH analog drugs or (ii) surgical castration; (b) prior treatment failure on one or more androgen receptor antagonist drugs; and (c) no prior exposure to chemotherapy for prostate cancer.

(3) Defined as prostate cancer patients who meet each of the following two criteria: (a) prior treatment failure on either (i) one or more LHRH analog drugs or (ii) surgical castration; and (b) no prior treatment failure on one or more androgen receptor antagonist drugs.

(4) An additional milestone payment of $7 million is payable upon the first to occur of: (a) first approval of a marketing application in the United States with a label encompassing 2nd line prostate cancer patients; (b) first approval of a marketing application in the first major country in Europe with a label encompassing 2nd line prostate cancer patients; (c) first approval of a marketing application in Japan with a label encompassing 2nd line prostate cancer patients; or (d) first patient dosed in a Phase 3 clinical trial other than the PREVAIL trial that is designed specifically to support receipt of marketing approval in 2nd line patients.

(5) These milestone payments totaling $58.0 million have been previously earned and the related payments have been received.

Schedule Of Collaboration Revenue

Collaboration revenue was as follows for the periods presented:

	Years Ended December 31,
	2012		2011		2010
Collaboration revenue:
Attributable to U.S. XTANDI sales	$	35,752	$	—	$	—
Attributable to ex-U.S. XTANDI sales		—		—		—
Attributable to up-front and milestone payments		145,944		60,389		62,508
Total	$	181,696	$	60,389	$	62,508

Schedule Of Collaboration Revenue Attributable To Sales

Collaboration revenue attributable to U.S. XTANDI sales for the year ended December 31, 2012 was as follows:

	Year Ended December 31, 2012
Net U.S. sales (as reported by Astellas)	$	71,504
Shared U.S. development and commercialization costs		(88,908	)
Pre-tax U.S. profit (loss)	$	(17,404	)
Medivation’s share of pre-tax U.S. profit (loss)	$	(8,702	)
Reimbursement of Medivation’s share of shared U.S. costs		44,454
Collaboration revenue attributable to U.S. XTANDI sales	$	35,752

Schedule Of Collaboration Revenue Attributable To Up-Front And Milestone Payments

The following table summarizes collaboration revenue attributable to up-front and milestone payments for the periods presented:

	Years Ended December 31,
	2012		2011		2010
Collaboration revenue attributable to up-front and milestone payments:
From Astellas	$	73,914	$	24,374	$	23,492
From Pfizer		72,030		36,015		39,016
Total	$	145,944	$	60,389	$	62,508

Deferred Revenue

Deferred revenue consisted of the following as of the dates presented:

	December 31,
	2012		2011
Current portion of deferred revenue:
From Astellas	$	33,862	$	23,747
From Pfizer		—		36,015
Total	$	33,862	$	59,762
Long-term portion of deferred revenue:
From Astellas	$	8,465	$	47,494
From Pfizer		—		36,015
Total	$	8,465	$	83,509

Development And Commercialization Cost-Sharing Payments

The following table summarizes the reductions in R&D expenses related to cost-sharing payments for the periods presented:

	Years Ended December 31,
	2012		2011		2010
Development cost-sharing payments from Astellas	$	47,473	$	44,285	$	34,125
Development cost-sharing payments from Pfizer		1,740		12,365		29,139
Total	$	49,213	$	56,650	$	63,264

The following table summarizes the (increases) reductions in SG&A expenses related to cost-sharing payments for the periods presented:

	Years Ended December 31,
	2012			2011			2010
Commercialization cost-sharing payments (to) from Astellas	$	(3,437	)	$	(472	)	$	520
Commercialization cost-sharing payments from (to) Pfizer		9			32			(1,084	)
Total	$	(3,428	)	$	(440	)	$	(564	)

Collaboration Receivables

At December 31, 2012 and 2011, collaboration receivables from Astellas and Pfizer were as follows:

	December 31,
	2012		2011
From Astellas	$	35,458	$	10,554
From Pfizer		—		1,991
Total	$	35,458	$	12,545